New hope for advanced cervical cancer: triple-drug combo tested in clinical trial
NCT ID NCT07177716
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests whether adding two experimental drugs (LB1410 and LB4330) to the standard drug lenvatinib works better than chemotherapy for people with advanced cervical cancer that has returned or spread. About 120 participants will be randomly assigned to one of the treatment groups. The goal is to see if the new combinations shrink tumors and delay cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.